title: Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?
authors.affiliation: Department of Hematology/Oncology, Cleveland Clinic Foundation, Ohio 44195, USA.
authors.forename: M
authors.initials: M
authors.lastname: Markman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017048:Health Care Costs; D006801:Humans
chemical_list: D000970:Antineoplastic Agents